Several individuals enrolled in a phase 3 trial for Eli Lilly's (NYSE:LLY) next-generation obesity drug, retatrutide, say that while they have seen incredible weight loss, the trial has also come ...

Retatrutide is a synthetic peptide, which research indicates functions as a triple agonist for type 2 diabetes and weight loss. Peptides, small chains of amino acids, have been hypothesized to ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...

A new weight loss injection called retatrutide has shown remarkable results in helping users shed weight quickly. However, recent research suggests that the drug, which is developed by the makers of ...

Early trials of the drug, retatrutide, have already shown it can help people shed a quarter of their body weight in under a year — almost twice as effective as Ozempic. But now scientists ...